Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Study of Surufatinib in Advanced Solid Tumors
ChiCTR2400084499Phase 4Not yet recruiting
- Sponsor
- Central Hospital of Fengxian District, Shanghai
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 6 more, sponsored by Central Hospital of Fengxian District, Shanghai. Primary endpoint: Progression-Free Survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2400084499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084499.